- CFC inhalers to be phased out by end of year, FDA says
- FDA advisory committee to consider OTC NDA for asthma-relieving Primatene HFA
- FDA advisory committees turn down Primatene HFA application for OTC status
- Prasco begins distribution of doxercalciferol capsules
- Aerocrine AB: Primary care trial supports FeNO-guided asthma treatment
CINCINNATI, Ohio — Prasco Labs is distributing an authorized generic version of a respiratory drug under an agreement with the branded drug's manufacturer.
Prasco said Monday that it had entered an agreement with Sunovion Pharmaceuticals to distribute an authorized generic version of Sunovion's Xopenex (levalbuterol hydrochloride) inhalation solution in the 1.25-mg/3-mL, 0.63-mg/3-mL and 0.31-mg/3-mL strengths. An authorized generic is a branded drug marketed under its generic name at a reduced price, usually under a partnership between the branded drug's manufacturer and a third-party company.
Xopenex is used to treat and prevent bronchospasm in patients ages 6 years and older with reversible obstructive airway disease. Xopenex had sales of about $474 million during the 12-month period ended in June, according to IMS Health.